Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

Feature | Stents | February 11, 2020 | Saloni Walimbe
Cardiovascular diseases (CVDs) are among the leading causes of death across the globe. For patients suffering from high...
 Bioresorbable stent Abbott Absorb stent
News | November 08, 2019
November 8, 2019 — The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients...
News | Stents Bioresorbable | November 07, 2019
November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was taken off the market due...
Global Cardiovascular Stent Market Poised for Almost 7 Percent Growth Through 2025
News | Stents | August 21, 2019
August 21, 2019 — Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the...
The cardiovascular innovation cycle presented by TCT Course Director Martin Leon, M.D. at TCT 2018. #TCT2018 #TCT #TCT18

The cardiovascular innovation cycle, presented by TCT Course Director Martin Leon, M.D., at TCT 2018.

Blog | Cath Lab | October 16, 2018
There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on...
Bioresorbable stents (BRS) in development presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. #TCT #TCT2018

Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. (Pghoto by Dave Fornell)

Feature | Stents Bioresorbable | October 12, 2018 | Dave Fornell, Editor
Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology...
A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. #TCT #TCT2018 #TCT18 #BRS #bioresorbablestents #bioresorbablescaffolds

A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. 

News | Stents Bioresorbable | October 12, 2018
October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom...
Videos | October 11, 2018
A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president,...
Videos | TCT | October 03, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the expo...
Magnitude Bioresorbable Scaffold Shows Low MACE, Restenosis Rates at Nine Months
News | Stents Bioresorbable | October 01, 2018
October 1, 2018 — New results from the RENASCENT studies presented at the Transcatheter Cardiovascular Therapeutics (...
Videos | Stents Bioresorbable | August 06, 2018
Patrick Serruys, M.D., Ph.D., Imperial College London, explains where development of bioresorbable scaffolds stands in...
Amaranth's Fortitute bioresorbable stent scaffold. The company is developing smaller strut BRS.  Data presented at EuroPCR 2018
Feature | Stents Bioresorbable | June 19, 2018
June 19, 2018 – Amaranth Medical offered new details about its 85-micron Defiance bioresorbable scaffold (BRS) recently...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
May 31, 2018 – Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the...
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or...